SPRO
Spero Therapeutics Inc
NASDAQ: SPRO · HEALTHCARE · BIOTECHNOLOGY
$1.17
+2.63% today
Updated 2026-10-28
Market cap
$62.31M
P/E ratio
7.64
P/S ratio
1.33x
EPS (TTM)
$0.14
Dividend yield
—
52W range
$1 – $3
Volume
0.6M
WallStSmart proprietary scores
54
out of 100
Grade: C
Hold
Investment rating
6.0
Growth
B7.0
Quality
B+7.5
Profitability
B+6.7
Valuation
B5/9
Piotroski F-Score
Moderate
-3.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
$5.00
+327.35%
12-Month target
$2.91
+148.72%
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ ROE 35.10% — strong efficiency
+ Debt/equity 0.05x — low leverage
Risks
- Altman Z -3.36 — distress zone
- Negative free cash flow $-5.36M
- Revenue declining -95.60% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $48.58M | $103.78M | $47.98M | $59.62M | $47.00M |
| Net income | $-46.41M | $22.81M | $-68.57M | $8.57M | $-9.55M |
| EPS | — | — | — | — | $0.14 |
| Free cash flow | $-7.73M | $-32.99M | $-23.44M | $-12.62M | $-5.36M |
| Profit margin | -95.55% | 21.98% | -142.91% | 14.38% | 15.70% |
Peer comparison
Smart narrative
Spero Therapeutics Inc trades at $1.17. representing a P/E of 7.64x trailing earnings. Our Smart Value Score of 54/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of -3.36, it sits in the distress. TTM revenue stands at $47.00M. with profit margins at 15.70%.
Frequently asked questions
What is Spero Therapeutics Inc's stock price?
Spero Therapeutics Inc (SPRO) trades at $1.17, on a P/E of 7.6x and a P/S of 1.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Spero Therapeutics Inc overvalued?
Spero Therapeutics Inc carries a Smart Value Score of 54/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Spero Therapeutics Inc (SPRO)?
The 12-month analyst consensus target is $5.00, about 327.4% above the current $1.17. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Spero Therapeutics Inc's revenue?
Spero Therapeutics Inc's trailing twelve-month revenue is $47.00M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Spero Therapeutics Inc's Altman Z-Score is -3.36, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.33x
ROE35.10%
Beta1.50
50D MA$1.18
200D MA$2.01
Shares out0.06B
Float0.05B
Short ratio—
Avg volume0.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—